CY1114130T1 - Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης - Google Patents

Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης

Info

Publication number
CY1114130T1
CY1114130T1 CY20131100591T CY131100591T CY1114130T1 CY 1114130 T1 CY1114130 T1 CY 1114130T1 CY 20131100591 T CY20131100591 T CY 20131100591T CY 131100591 T CY131100591 T CY 131100591T CY 1114130 T1 CY1114130 T1 CY 1114130T1
Authority
CY
Cyprus
Prior art keywords
compounds
bradykinin
compressors
production
salts
Prior art date
Application number
CY20131100591T
Other languages
English (en)
Inventor
Norbert Hauel
Angelo Ceci
Henri Doods
Ingo Konetzki
Juergen Mack
Henning Priepke
Annette Schuler-Metz
Rainer Walter
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1114130T1 publication Critical patent/CY1114130T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

Αντικείμενο της παρούσας εφεύρεσης είναι οι ενώσεις του γενικού τύπου (Ι), στον οποίο η, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 και Χ ορίζονται όπως περιγράφεται παρακάτω, τα εναντιομερή τους, τα διαστερεοϊσομερή τους, τα μείγματα τους και τα άλατα τους, ιδιαιτέρως τα φυσιολογικά συμβατά άλατα τους με οργανικά ή ανόργανα οξέα ή βάσεις, τα οποία έχουν πολύτιμες ιδιότητες, η παραγωγή τους, φάρμακα, τα οποία περιέχουν τις φαρμακολογικά δραστικές ενώσεις, η παραγωγή τους και η χρήση τους.
CY20131100591T 2009-02-26 2013-07-11 Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης CY1114130T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09153778 2009-02-26
EP10711628.7A EP2401256B1 (de) 2009-02-26 2010-02-23 Verbindungen als Bradykinin-B1-Antagonisten

Publications (1)

Publication Number Publication Date
CY1114130T1 true CY1114130T1 (el) 2016-07-27

Family

ID=42307969

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100591T CY1114130T1 (el) 2009-02-26 2013-07-11 Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης

Country Status (37)

Country Link
US (3) US20100240669A1 (el)
EP (1) EP2401256B1 (el)
JP (1) JP5629274B2 (el)
KR (1) KR101660357B1 (el)
CN (1) CN102414177B (el)
AP (1) AP2011005808A0 (el)
AR (1) AR075599A1 (el)
AU (1) AU2010217606C1 (el)
BR (1) BRPI1008779A2 (el)
CA (1) CA2759126C (el)
CL (1) CL2011002076A1 (el)
CO (1) CO6430425A2 (el)
CY (1) CY1114130T1 (el)
DK (1) DK2401256T3 (el)
EA (2) EA024656B1 (el)
EC (2) ECSP11011304A (el)
ES (1) ES2421630T3 (el)
GE (1) GEP20135933B (el)
HK (1) HK1164315A1 (el)
HR (2) HRP20130666T1 (el)
IL (1) IL214129A (el)
MA (1) MA33238B1 (el)
ME (1) ME01526B (el)
MX (1) MX2011008553A (el)
MY (1) MY153941A (el)
NZ (1) NZ594674A (el)
PE (1) PE20120360A1 (el)
PL (1) PL2401256T3 (el)
PT (1) PT2401256E (el)
RS (2) RS52801B (el)
SG (1) SG173698A1 (el)
SI (1) SI2401256T1 (el)
TN (2) TN2011000438A1 (el)
TW (1) TW201041870A (el)
UA (2) UA105923C2 (el)
UY (2) UY32463A (el)
WO (1) WO2010097372A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
WO2009027450A1 (de) 2007-08-29 2009-03-05 Boehringer Ingelheim International Gmbh Neue bradykinin b1-antagonisten
CL2008002542A1 (es) 2007-08-31 2009-01-02 Eisai R&D Man Co Ltd Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
AP2011005808A0 (en) * 2009-02-26 2011-08-31 Boehringer Ingelheim Int Compounds as bradykinin B1 antagonists.
PT2539323E (pt) * 2010-02-23 2015-02-16 Boehringer Ingelheim Int Compostos como antagonistas da bradicinina b1
WO2012022794A1 (de) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Pyridazinderivative als bradykinin b1 rezeptor antagonsiten
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) * 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
US8877766B2 (en) * 2013-02-15 2014-11-04 Peter F. Kador Neuroprotective multifunctional antioxidants and their monofunctional analogs
JP6072308B2 (ja) 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉｉ
US20160310477A1 (en) * 2013-12-20 2016-10-27 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mek type 1 and erk inhibitors
RU2690188C2 (ru) 2017-05-26 2019-05-31 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый мультитаргетный препарат для лечения заболеваний у млекопитающих
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4342937B2 (ja) * 2001-07-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン
AR038377A1 (es) * 2002-02-08 2005-01-12 Merck & Co Inc Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
ES2256727T3 (es) 2002-02-08 2006-07-16 MERCK & CO., INC. Derivados de n-bifenilmetil aminocicloalcanocarboxamida.
US7163951B2 (en) * 2002-08-29 2007-01-16 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
CA2534188A1 (en) * 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN1926136A (zh) * 2004-03-02 2007-03-07 默克公司 作为缓激肽拮抗剂的氨基环丙烷羧酰胺衍生物
WO2006120176A2 (en) 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
HUP0600808A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
WO2009027450A1 (de) * 2007-08-29 2009-03-05 Boehringer Ingelheim International Gmbh Neue bradykinin b1-antagonisten
AP2011005808A0 (en) * 2009-02-26 2011-08-31 Boehringer Ingelheim Int Compounds as bradykinin B1 antagonists.

Also Published As

Publication number Publication date
CN102414177A (zh) 2012-04-11
MX2011008553A (es) 2011-09-09
WO2010097372A1 (de) 2010-09-02
TW201041870A (en) 2010-12-01
CL2011002076A1 (es) 2012-02-17
RS52801B (en) 2013-10-31
MY153941A (en) 2015-04-15
TN2011000438A1 (en) 2013-03-27
SI2401256T1 (sl) 2013-08-30
UY33238A (es) 2011-09-30
US20120142695A1 (en) 2012-06-07
ES2421630T3 (es) 2013-09-04
RS53710B1 (en) 2015-04-30
EP2401256A1 (de) 2012-01-04
JP5629274B2 (ja) 2014-11-19
PE20120360A1 (es) 2012-04-14
BRPI1008779A2 (pt) 2020-12-22
ECSP11011304A (es) 2011-10-31
JP2012518672A (ja) 2012-08-16
CO6430425A2 (es) 2012-04-30
US20100240669A1 (en) 2010-09-23
US8372838B2 (en) 2013-02-12
PT2401256E (pt) 2013-05-13
CN102414177B (zh) 2014-07-02
IL214129A (en) 2015-08-31
EA201101209A1 (ru) 2012-04-30
HRP20150167T1 (en) 2015-05-22
GEP20135933B (en) 2013-10-10
EA023437B1 (ru) 2016-06-30
ECSP12012161A (es) 2012-10-30
AU2010217606C1 (en) 2017-01-19
RS53710B2 (sr) 2018-07-31
EA201201167A1 (ru) 2013-04-30
AU2010217606A1 (en) 2011-09-08
HK1164315A1 (en) 2012-09-21
US20130131075A1 (en) 2013-05-23
UA105923C2 (uk) 2014-07-10
UA108373C2 (xx) 2015-04-27
MA33238B1 (fr) 2012-05-02
PL2401256T3 (pl) 2013-09-30
TN2012000417A1 (en) 2014-01-30
AR075599A1 (es) 2011-04-20
UY32463A (es) 2010-09-30
ME01526B (me) 2014-04-20
NZ594674A (en) 2013-12-20
SG173698A1 (en) 2011-09-29
DK2401256T3 (da) 2013-06-03
KR20110120913A (ko) 2011-11-04
CA2759126C (en) 2017-08-22
IL214129A0 (en) 2011-08-31
CA2759126A1 (en) 2010-09-02
HRP20130666T1 (en) 2013-10-11
AP2011005808A0 (en) 2011-08-31
HRP20150167T4 (hr) 2018-04-20
AU2010217606B2 (en) 2016-07-07
KR101660357B1 (ko) 2016-09-27
EP2401256B1 (de) 2013-04-17
EA024656B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
CY1114130T1 (el) Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης
CY1116182T1 (el) Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης
CY1123237T1 (el) Αρυλο και ετεροαρυλο συμπυκνωμενες λακταμες
CY1118656T1 (el) Παραγωγο πυριδονης
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1122944T1 (el) Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
CY1122062T1 (el) Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1118346T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1124022T1 (el) Σχημα χορηγησης για νιτροκατεχολες
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
PH12014502788B1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1115933T1 (el) Διϋποκατεστημενες ενωσεις τετραϋδροφουρανυλιου ως ανταγωνιστες toy β1-υποδοχεα βραδυκινινης
CY1112670T1 (el) Παραγωγα του 5.6-bisaryl-2-πυριδιν-καρβοξαμιδιου, η παρασκευη τους και η εφαρμογη τους σε θεραπευτικη αγωγη ως ανταγωνιστες των υποδοχεων στην ουροτενσινη ii
CY1114759T1 (el) Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες
CY1120420T1 (el) Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης
CY1116542T1 (el) Νεα παραγωγα (συμπυκνωμενης ετεροκυκλο-πιπεριδινης)-(πιπεραζινυλ)-1-αλκανονης ή (συμπυκνωμενης ετεροκυκλο-πυρρολιδινης)-(πιπεραζινυλ)-1-αλκανονης, και χρηση αυτων ως αναστολεων p75
CY1113129T1 (el) Παραγωγα 5,6-δισαρυλ-2- πυριδινο- καρβοξαμιδιου, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη ως ανταγωνιστες των υποδοχεων ουροτενσινης ii
CY1112809T1 (el) Παραγωγα της ινδολ-2-ονης δισυποκατεστημενα στη θεση 3, η παρασκευη τους και η θεραπευτικη εφαρμογη τους